Precigen, Inc.

NASDAQ:PGEN

Biotechnology

Healthcare
$4.27 -2.08%

-$0.10 today

Market cap
$1.53B
Beta
1.06
P/E (TTM)
-7.1
EPS (TTM)
-$0.65
52W Low $1.39High $5.47

Volume 4.27M

Average 4.72M

PGEN Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Precigen, Inc.NASDAQ: PGEN

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares growth accelerates

Q2 FY2026 weighted avg shares of 356.89M shares rose 20.4% year over year, ahead of the +10.4% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 14.0% from the prior quarter. Over 3 fiscal years it compounded at +15.0% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +20.4% holds above the trailing-twelve-month pace of +10.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
356.89M+14.0% QoQ
Last fiscal yearDec 2025
304.71M+13.8% YoY
LTMJun 2026
319.82M+10.4% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.4%——
1 year+13.8%——
3-year CAGR+15.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
304.71M USD
Year-over-year change
+13.8%
4-year CAGR
+11.4%

Weighted Avg Shares vs competitors

How PGEN compares with its peers on the latest reported figures

  • PGEN's LTM Jun 2026 weighted avg shares of 319.82M shares is the highest of the 8 companies compared; the peer median is 90.28M shares.
  • Its year-over-year change of +10.4% is the 4th highest of 8, against a peer median of +9.3%.
  • Over three fiscal years its annual growth of +15.0% compares with a peer median of +12.1%.
PGEN Competitors Peer median
Weighted Avg Shares for PGEN and competitors
Company Period LTM YoY 3-year CAGR
PGENPrecigen, Inc.LTM Jun 2026319.82M +10.4%+15.0%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026111.46M +12.7%+17.7%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026110.2M +9.3%+12.1%
CRSPCRISPR Therapeutics AGLTM Sep 202694.81M +8.4%+5.0%
EDITEditas Medicine, Inc.LTM Mar 202690.28M +9.3%+8.9%
ABEOAbeona Therapeutics Inc.LTM Mar 202654.09M +20.9%+88.9%
RGNXREGENXBIO Inc.LTM Mar 202651.84M +1.8%+6.1%
DTILPrecision BioSciences, Inc.LTM Mar 202612.13M +61.6%+63.6%
Peer median (excluding PGEN) 90.28M+9.3%+12.1%

Competitors are the stored peer set for PGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue14.27M26.91M6.23M3.93M9.68M
Cost of Revenue53.68M6.34M6.12M4.27M6.1M
Gross Profit(39.41M)20.57M106K(342K)3.59M
Gross Margin-276.2%76.4%1.7%-8.7%37.1%
Research & Development47.93M47.17M48.61M53.07M40.06M
Selling, General & Admin048.01M40.42M41.29M70.13M
Operating Expenses52.54M96.3M99.86M134.69M110.19M
Depreciation & Amortization13.76M10.77M6.67M4.53M3.2M
EBITDA(77.64M)(62.43M)(89.23M)(123.5M)(243.57M)
EBITDA Margin-544.2%-232.0%-1433.3%-3146.4%-2515.2%
Operating Income(91.95M)(75.73M)(99.76M)(135.03M)(106.6M)
Operating Margin-644.5%-281.4%-1602.5%-3440.2%-1100.8%
Interest Income171K133K3.24M1.42M3.22M
Interest Expense18.76M6.77M468K6K3.87M
Other Income / Expenses(19.02M)(4.24M)3.4M7M(144.04M)
Income Before Tax(110.97M)(79.97M)(96.36M)(128.03M)(250.64M)
Pre-Tax Margin-777.8%-297.2%-1548.0%-3261.9%-2588.2%
Income Tax Expense(160K)(189K)(458K)(1.79M)3K
Net Income(92.17M)28.32M(95.9M)(126.24M)(250.64M)
Net Margin-646.0%105.2%-1540.6%-3216.2%-2588.2%
EPS (Basic)(0.47)(0.33)(0.39)(0.47)(1.41)
EPS (Diluted)(0.47)(0.40)(0.39)(0.47)(1.41)
Weighted Avg Shares197.76M200.36M244.54M267.73M304.71M
Weighted Avg Shares (Diluted)197.76M200.36M244.54M267.73M304.71M

Precigen, Inc.

NASDAQ:PGEN

Intrinsic Alpha fair value

Locked

Current Price

$4.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.